Literature DB >> 3401630

Effects of atropine and tetrodotoxin on neurotensin-induced ileal sodium transport in the dog.

D Mailman1.   

Abstract

1. Neurotensin was infused intravenously, in the presence or absence of intravenous atropine or intraarterial tetrodotoxin, into dogs anaesthetized with sodium pentobarbitone. Net and unidirectional fluxes of sodium and blood flows in the ileum were measured. Arterial and mesenteric venous blood pressures, haematocrits and plasma total solids were also determined. 2. Neurotensin caused a transient increase in net sodium absorption which was not associated with significant changes in unidirectional fluxes. This was followed by prolonged net secretion which was associated with an increase in unidirectional sodium secretion and a smaller decrease in sodium absorption. Potassium secretion was also increased when net sodium secretion increased. 3. Neurotensin increased haematocrit and total solids and decreased arterial pressure at the same time that secretion occurred. 4. Atropine blocked all the cardiovascular effects of neurotensin and reduced its early effects on both absorption and secretion but not the later effects on secretion. Tetrodotoxin only blocked the increase in absorption but not the secretion or the cardiovascular effects. 5. It was concluded that there is a cholinergic step in the cardiovascular effects of neurotensin and that the early effects of neurotensin on secretion are due to active secretion supported by fluid leakage from the plasma. The later effects of neurotensin on secretion do not have a cholinergic step and are due primarily to an active secretion. The increased absorption is mediated partly through intrinsic nerves of the gut.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401630      PMCID: PMC1853915          DOI: 10.1111/j.1476-5381.1988.tb11506.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Neurohumoral control of ileal electrolyte transport.

Authors:  R J Miller; J F Kachur; M Field; J Rivier
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

2.  Mechanisms of the cardiovascular effects of neurotensin.

Authors:  F Rioux; R Kérouac; R Quirion; S St-Pierre
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

3.  Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles.

Authors:  S E Leeman; R E Carraway
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

Review 4.  Intestinal microcirculation and transmucosal fluid transport.

Authors:  D N Granger
Journal:  Am J Physiol       Date:  1981-05

5.  Mechanism of glucagon-induced intestinal secretion.

Authors:  D N Granger; P R Kvietys; W H Wilborn; N A Mortillaro; A E Taylor
Journal:  Am J Physiol       Date:  1980-07

6.  Secretion of neurotensin and its effects on the jejunum in the dog.

Authors:  P G Reasbeck; G O Barbezat; A Shulkes; J Leader
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

7.  PGE1-induced intestinal secretion: mechanism of enhanced transmucosal protein efflux.

Authors:  D N Granger; J S Shackleford; A E Taylor
Journal:  Am J Physiol       Date:  1979-06

Review 8.  Local modulation of intestinal ion transport by enteric neurons.

Authors:  E J Tapper
Journal:  Am J Physiol       Date:  1983-05

9.  Effects of glucagon on canine intestinal sodium and water fluxes and regional blood flow.

Authors:  S N MacFerran; D Mailman
Journal:  J Physiol       Date:  1977-03       Impact factor: 5.182

10.  The calculation of transfer rates in two compartment systems not in dynamic equilibrium.

Authors:  E Y BERGER; J M STEELE
Journal:  J Gen Physiol       Date:  1958-07-20       Impact factor: 4.086

View more
  1 in total

1.  Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.

Authors:  U Spöhrer; H Thiermann; R Klimmek; P Eyer
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.